诊断学理论与实践 ›› 2023, Vol. 22 ›› Issue (02): 166-171.doi: 10.16150/j.1671-2870.2023.02.010
收稿日期:
2023-01-12
出版日期:
2023-04-25
发布日期:
2023-08-31
通讯作者:
林孝怡 E-mail: owl_linxy@163.com
Received:
2023-01-12
Online:
2023-04-25
Published:
2023-08-31
摘要:
目的:探讨血清游离轻链(serum free light chain,sFLC)对单克隆免疫球蛋白相关肾病的辅助诊断效能,及其与不同病因肾损伤患者肾功能分期间的相关性。方法:收集2017年1月至2021年9月上海交通大学医学院附属瑞金医院收治的非单克隆免疫球蛋白相关肾损伤患者368例、单克隆免疫球蛋白相关肾病患者64例和正常对照30例。检测各组sFLC,并使用GraphPad Prism v9.0软件进行统计学分析。结果:单克隆免疫球蛋白相关肾病患者的sFLC水平显著高于非单克隆免疫球蛋白相关肾损伤患者(sFLCκ,453.0 mg/L比53.2 mg/L; sFLCλ,382.5 mg/L比56.5 mg/L),且sFLCκ/λ比值异常。当sFLCκ/λ比值阈值设为1.925时,其诊断κ型单克隆免疫球蛋白病的灵敏度为84.4%,特异度为97.0%,受试者操作特征曲线的曲线下面积(area under the curve, AUC)为0.933 9。当sFLCκ/λ比值阈值设为0.455时,其诊断λ型单克隆免疫球蛋白病的灵敏度为84.4%,特异度为87.2%,AUC为0.915 9。sFLC水平与非单克隆免疫球蛋白相关肾病患者肾功能分期间的相关性(r=0.7)优于单克隆免疫球蛋白相关肾病患者(r=0.4),且sFLC水平与患者肾功能分期间的相关性较sFLCκ/λ比值(r<0.3)更高。结论:sFLCκ/λ比值可用于单克隆免疫球蛋白相关肾病与非单克隆免疫球蛋白相关肾损伤的鉴别诊断,而sFLC水平较sFLCκ/λ比值更适于患者的肾功能评估。
中图分类号:
谢雅琼, 林孝怡. 血清游离轻链在鉴别诊断不同病因肾病的应用价值及其与患者肾功能分期的相关性分析[J]. 诊断学理论与实践, 2023, 22(02): 166-171.
XIE Yaqiong, LIN Xiaoyi. Value of serum-free light chain assay in differential diagnosis and staging of nephropathy of various etiologies[J]. Journal of Diagnostics Concepts & Practice, 2023, 22(02): 166-171.
表1
各组患者sFLC水平及肾功能相关指标检测结果
Group | n | sFLCκ(mg/L) | sFLCλ(mg/L) | sFLCκ/λ | Urea(mmol/L) | Creatinine(μmol/L) | Uric acid(μmol/L) |
---|---|---|---|---|---|---|---|
Normal range | 3.3-19.4 | 5.7-26.3 | 0.26-1.65 | 2.5-7.1 | 53.0-97.0 | 160-430 | |
Normal control | 30 | 10.6±4.7 | 11.1±4.6 | 1.12±0.63 | 3.9±1.3 | 69.3±12.5 | 268.7±88.5 |
Cardiovascular disease | 47 | 63.4±71.3* | 60.7±54.1* | 1.06±0.94 | 13.8±9.2 | 294.1±273.5 | 435.3±96.4 |
Diabetes | 38 | 68.6±51.9* | 74.2±51.0* | 1.13±1.19 | 15.1±7.7 | 302.1±265.2 | 390.1±100.7 |
Primary glomerulonephritis | 56 | 62.3±100.2* | 56.8±48.3* | 0.89±0.57 | 12.8±10.1 | 257.1±309.6 | 373.4±141.2 |
Autoimmune disease | 121 | 54.6±86.4* | 55.0±52.6* | 0.83±0.45 | 8.8±7.5 | 146.8±169.5 | 385.3±117.1 |
IgA nephropathy | 106 | 36.6±53.8* | 49.9±67.7* | 0.72±0.33# | 8.8±6.0 | 163.3±181.4 | 376.9±89.8 |
Monoclonal gammopathy with κ isotype | 32 | 453.0±1275.0* | 28.6±23.3* | 22.6±41.7* | 14.3±10.8 | 264.9±215.0 | 413.3±184.4 |
Monoclonal gammopathy with λ isotype | 32 | 21.9±15.6* | 382.5±728.3* | 0.3±0.2# | 10.7±8.3 | 214.7±234.2 | 358.2±133.2 |
表2
sFLCκ水平及sFLCκ/λ比值诊断对单克隆免疫球蛋白相关肾病的效能
Disease | Parameter | Cut-off value | Sensitivity(%) | Specificity(%) | AUC |
---|---|---|---|---|---|
Monoclonal gammopathy with κ isotype | sFLCκ | >176.5 mg/L | 62.5 | 92.1 | 0.832 6 |
sFLCκ/λ | >1.925 | 84.4 | 97.0 | 0.933 9 | |
Monoclonal gammopathy with λ isotype | sFLCλ | >82.3 mg/L | 68.8 | 79.1 | 0.797 6 |
sFLCκ/λ | <0.455 | 84.4 | 87.2 | 0.915 9 |
表3
sFLC水平及sFLCκ/λ比值与各组患者肾功能分期间的相关性分析
Groups | sFLCκ | sFLCλ | sFLCκ/λ | |
---|---|---|---|---|
Non-monoclonal gammopathy | r | 0.688 7 | 0.661 2 | 0.300 0 |
P | <0.000 1 | <0.000 1 | <0.000 1 | |
Cardiovascular disease | r | 0.835 5 | 0.894 2 | / |
P | <0.000 1 | <0.000 1 | ns | |
Diabetes | r | 0.767 2 | 0.727 1 | / |
P | <0.000 1 | <0.000 1 | ns | |
Primary glomerulonephritis | r | 0.772 8 | 0.721 7 | 0.501 0 |
P | <0.000 1 | <0.000 1 | <0.000 1 | |
Autoimmune disease | r | 0.516 8 | 0.537 9 | / |
P | <0.000 1 | <0.000 1 | ns | |
IgA nephropathy | r | 0.689 8 | 0.687 5 | 0.211 0 |
P | <0.000 1 | <0.000 1 | 0.029 9 | |
P | 0.003 9 | 0.006 8 | ns | |
Monoclonal gammopathy with | r | / | 0.524 4 | / |
κ isotype | P | ns | 0.002 1 | ns |
Monoclonal gammopathy with | r | 0.478 0 | 0.610 1 | -0.371 9 |
λ isotype | P | 0.005 7 | 0.000 2 | 0.036 1 |
[1] |
DISPENZIERI A, KYLE R, MERLINI G, et al. International Myeloma Working Group guidelines for serum-free light chain analysis in multiple myeloma and related disor-ders[J]. Leukemia, 2009, 23(2):215-224.
doi: 10.1038/leu.2008.307 |
[2] |
GRAN C, AFRAM G, LIWING J, et al. Involved free light chain: an early independent predictor of response and progression in multiple myeloma[J]. Leuk Lymphoma, 2021, 62(9):2227-2234.
doi: 10.1080/10428194.2021.1907370 URL |
[3] |
HUTCHISON C A, BASNAYAKE K, COCKWELL P. Serum free light chain assessment in monoclonal gammopathy and kidney disease[J]. Nat Rev Nephrol, 2009, 5(11):621-628.
doi: 10.1038/nrneph.2009.151 pmid: 19786994 |
[4] |
YADAV P, SATHICK I J, LEUNG N, et al. Serum free light chain level at diagnosis in myeloma cast nephropathy-a multicentre study[J]. Blood Cancer J, 2020, 10(3):28.
doi: 10.1038/s41408-020-0295-4 pmid: 32127527 |
[5] |
OLSEN E, VAN GALEN G. Chronic renal failure-causes, clinical findings, treatments and prognosis[J]. Vet Clin North Am Equine Pract, 2022, 38(1):25-46.
doi: 10.1016/j.cveq.2021.11.003 URL |
[6] |
PATTRAPORNPISUT P, AVILA-CASADO C, REICH H N. IgA Nephropathy: Core Curriculum 2021[J]. Am J Kidney Dis, 2021, 78(3):429-441.
doi: 10.1053/j.ajkd.2021.01.024 pmid: 34247883 |
[7] | 中国医师协会血液科医师分会,中华医学会血液学分会. 中国多发性骨髓瘤诊治指南(2022年修订)[J]. 中华内科杂志, 2022, 61(5):480-487. |
Chinese Hematlology Association, Chinese Society of Hematology. Guidelines for the diagnosis and management of multiple myeloma in China (2022 revision)[J]. Chin J Intern Med, 2022, 61(5):480-487. | |
[8] |
LEVEY A S, ECKARDT K U, TSUKAMOTO Y, et al. Definition and classification of chronic kidney disease: a position statement from Kidney Disease: Improving Global Outcomes (KDIGO)[J]. Kidney Int, 2005, 67(6):2089-2100.
doi: 10.1111/j.1523-1755.2005.00365.x pmid: 15882252 |
[9] | CÁRDENAS M C, IÑIGO B, ORTEGA I, et al. Can urine studies be replaced by serum free light chains measurements to assign responses in multiple myeloma patients?[J]. Front Oncol, 2022, 12:1056293. |
[10] | 陈海飞, 侯健, 袁振刚, 等. 血清游离轻链的检测及其在不分泌型多发性骨髓瘤中的临床意义[J]. 中华血液学杂志, 2008, 29(2):113-116. |
CHEN H F, HOU J, YUAN Z G, et al. Detection of serum free light chain and its clinical significance in nonsecretory multiple myeloma[J]. Chin J Hematol, 2008, 29(2):113-116. | |
[11] | 宋萍, 安志明, 周小钢, 等. 血清游离轻链的检测及其在轻链型多发性骨髓瘤中的临床意义[J]. 中国实验血液学杂志, 2015, 23(5):1357-1361. |
SONG P, AN Z M, YUAN Z G, et al. Test of serum free light chain and its clinical significance in light chain multiple myeloma[J]. J Exp Hematol, 2015, 23(5):1357-1361. | |
[12] | 彭奕冰, 章黎华. 免疫球蛋白游离轻链的检测与临床应用[J]. 诊断学理论与实践, 2017, 16(5):468-471. |
PENG Y B, ZHANG L H. Detection of immunoglobulin free light chain and its clinical application[J]. J Diagn Concepts Pract, 2017, 16(5):468-471. | |
[13] | 陈文明. 我如何治疗伴肾功能不全的多发性骨髓瘤[J]. 中华血液学杂志, 2021, 42(2):97-100. |
CHEN W M. How I treat multiple myeloma with renal impairment[J]. Chin J Hematol, 2021, 42(2):97-100. | |
[14] |
SINGH G. Serum free light chain assay and κ/λ ratio performance in patients without monoclonal gammopathies: high false-positive Rate[J]. Am J Clin Pathol, 2016, 146(2):207-214.
doi: 10.1093/ajcp/aqw099 URL |
[15] |
SINGH G. Serum free light chain assay and κ/λ ratio: performance in patients with monoclonal gammopathy-high false negative rate for κ/λ ratio[J]. J Clin Med Res, 2017, 9(1):46-57.
doi: 10.14740/jocmr2802w pmid: 27924175 |
[16] |
LONG T E, INDRIDASON O S, PALSSON R, et al. Defining new reference intervals for serum free light chains in individuals with chronic kidney disease: results of the iStopMM study[J]. Blood Cancer J, 2022, 12(9):133.
doi: 10.1038/s41408-022-00732-3 pmid: 36100605 |
[17] |
HUTCHISON C A, HARDING S, HEWINS P, et al. Quantitative assessment of serum and urinary polyclonal free light chains in patients with chronic kidney disease[J]. Clin J Am Soc Nephrol, 2008, 3(6):1684-1690.
doi: 10.2215/CJN.02290508 URL |
[18] |
ERDEM B K, DAVRAN F, YILMAZ V T, et al. The association of serum-free light-chain levels with markers of renal function[J]. Ren Fail, 2015, 37(6):1057-1060.
doi: 10.3109/0886022X.2015.1052980 pmid: 26056734 |
[19] |
CAO D, SHOU L, WU Y, et al. The role of serum-free light chain ratios in the prediction of poor prognosis in multiple myeloma patients: a systematic review and meta-analysis[J]. Hematology, 2022, 27(1):1130-1139.
doi: 10.1080/16078454.2022.2127460 pmid: 36165782 |
[20] |
TACCHETTI P, ROCCHI S, ZAMAGNI E, et al. Role of serum-free light chain assay for defining response and progression in immunoglobulin secretory multiple myeloma[J]. Am J Hematol, 2022, 97(12):1607-1615.
doi: 10.1002/ajh.26747 pmid: 36198076 |
[1] | 郝家琪, 王鑫鹭, 胡晓帆, 潘晓霞, 徐静, 马骏. 急性肾小管间质性肾炎与急性肾小管坏死的临床鉴别分析[J]. 诊断学理论与实践, 2023, 22(02): 127-133. |
[2] | 王昭晖, 吴海波. 胃神经鞘瘤31例临床病理学分析[J]. 诊断学理论与实践, 2021, 20(06): 552-556. |
[3] | 徐丽梨, 王伟铭. 特发性肾性低尿酸血症相关的急性肾衰竭一例报告及文献复习[J]. 诊断学理论与实践, 2021, 20(02): 213-215. |
[4] | 杜月月, 杜军, 沈倩, 葛绾宇, 吴海波. Warthin瘤样甲状腺乳头状癌1例及临床病理观察[J]. 诊断学理论与实践, 2020, 19(02): 188-190. |
[5] | 吴霖, 郑戈, 陶婷. ACE基因多态性与老年人肾功能下降的相关性研究[J]. 诊断学理论与实践, 2019, 18(2): 204-208. |
[6] | 徐婷婷, 张文. 感染与中性粒细胞胞质抗体相关性血管炎间相关性的研究进展[J]. 诊断学理论与实践, 2019, 18(06): 698-703. |
[7] | 王建军, 陈雅, 樊祥山, 牛丰南. 脾脏硬化性血管瘤样结节性转化8例临床病理分析及文献复习[J]. 诊断学理论与实践, 2019, 18(05): 560-564. |
[8] | 常蕊, 徐嘉旭, 董海鹏, 吴梦雄, 赵雪松, 缪飞, 严福华. CT能谱成像在小肠克恩罗恩病活动度评估中的价值[J]. 诊断学理论与实践, 2019, 18(04): 432-435. |
[9] | 周鑫昀, 陈惠, 沈立松. 新型血清纤维化标志物在IgG4相关性疾病诊断评价中的临床价值[J]. 诊断学理论与实践, 2019, 18(03): 329-333. |
[10] | 姚洁洁, 朱樱, 詹维伟, 陈小松, 费晓春. 非肿块型乳腺导管内癌超声特征及与临床、病理、免疫组化指标表达间的相关性[J]. 诊断学理论与实践, 2018, 17(06): 676-681. |
[11] | 张国桢, 蔡庆, 张伟强. 早期微小肺腺癌CT影像与病理的相关性[J]. 诊断学理论与实践, 2018, 17(05): 490-493. |
[12] | 杨茹雪, 李楠, 周婷, 赵艳, 陈少华, 朱清, 冯振中. 皮肤黑素细胞病变的临床病理分析[J]. 诊断学理论与实践, 2018, 17(05): 566-571. |
[13] | 刘依萍, 唐圆圆, 徐奎, 滕晓明. 精子碎片指数与精子形态的关系研究[J]. 诊断学理论与实践, 2018, 17(01): 98-101. |
[14] | 唐陈月, 徐琛莹, 俞丽芬. 上海12 293例体检人群中酸相关性疾病的内镜检出特征分析[J]. 诊断学理论与实践, 2018, 17(01): 51-55. |
[15] | 朱培培, 邹珏, 陈军, 徐蓉蓉, 颜红柱. 颅内孤立性纤维性肿瘤/血管周细胞瘤20例临床病理特征分析[J]. 诊断学理论与实践, 2017, 16(06): 622-626. |
阅读次数 | ||||||
全文 |
|
|||||
摘要 |
|
|||||